The disclosure relates to compounds of the general formula (I), their pharmaceutically acceptable salts and a process for the preparation of these compounds, wherein the variables are as defined in the specification. These compounds can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress, which are selected from the following: ischemia, reperfusion injury, cardiovascular disorders, neurodegenerative disorders (including especially Alzheimer&rsquo；s disease and Huntington&rsquo；s disease), trauma, neuropsychiatric diseases (including especially depression and anxiety disorders), and liver, kidney and lung injuries.
